Clinical Trials Logo

Diarrhea clinical trials

View clinical trials related to Diarrhea.

Filter by:

NCT ID: NCT01571856 Completed - Clinical trials for Acute Gastroenteritis

Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants

Start date: July 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effect of zinc in acute watery diarrhea in children. The investigators will evaluate the effect of product versus placebo.

NCT ID: NCT01564290 Completed - Clinical trials for Acute Gastroenteritis

Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children

Start date: February 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effect of probiotic yogurt in acute watery diarrhea in children. The investigators will compare the effect of two different probiotics products.

NCT ID: NCT01559636 Completed - Diarrhea Clinical Trials

Diarrhea and Bivalent Oral Polio Vaccine Immunity

Start date: August 2012
Phase: N/A
Study type: Interventional

Global eradication of poliomyelitis has proven to be elusive. Although 99% of cases have been eliminated since 1988, outbreaks continue to occur, and new tools are needed to accelerate eradication. One concern in this effort is that some populations have decreased immunogenicity to oral poliovirus vaccine (OPV). Past studies have shown decreased seroimmunity to trivalent OPV (tOPV) in children with diarrhea. In 2009, bivalent OPV (bOPV) was recommended for use in immunization campaigns, and will likely replace tOPV in routine immunization in 2016. However, the effect of diarrhea on seroconversion to bOPV has not been studied. This project evaluated the effect of diarrhea on seroconversion to bOPV among infants who reside in Nepal. The investigators conducted a prospective, interventional study that assessed immune response to bOPV among infants with and without diarrhea. Immune responses were compared among infants with and without diarrhea. This study will result in a better understanding of the factors that decrease the ability of some children to seroconvert to OPV and be protected from poliomyelitis infection.

NCT ID: NCT01559545 Completed - Clinical trials for Clostridium Difficile Associated Diarrhea

A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis

Start date: March 2012
Phase: Phase 2
Study type: Interventional

Clostridium difficile bacteria can be a cause of significant diarrheal disease, particularly in people who have taken potent antibiotics. When C. difficile multiplies within the colon, it produces two toxins that cause inflammation and resultant abdominal pain, fever and diarrhea. Current treatment of mild to moderate disease is with immediate release metronidazole, an antibiotic that kills C. difficile. Dr. Reddy's Laboratories has developed a delayed release form of metronidazole to release just before the colon to increase the concentration of antibiotic in the colon to improve the effectiveness of metronidazole treatment and potentially to allow less whole body exposure to the antibiotic. This study will measure the amount of metronidazole in the blood and stool of patients with C. difficile associated diarrhea (CDAD) to confirm that the new formulations are releasing the antibiotic as designed, immediately before the colon.

NCT ID: NCT01558284 Completed - Clinical trials for Diarrhea- Irritable Bowel Syndrome

The Effect of Neu-P11 on Symptoms in Patients With D-IBS

Neu-P11
Start date: February 2012
Phase: N/A
Study type: Observational

Placebo controlled double-blind study with 40 patients who have an diarrhea-predominant IBS, 20 get Neu-P11, 20 get a placebo. Neu-P11 is a, Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist.

NCT ID: NCT01553747 Completed - Clinical trials for Irritable Bowel Syndrome

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Start date: May 29, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.

NCT ID: NCT01553591 Completed - Clinical trials for Irritable Bowel Syndrome

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Start date: May 29, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.

NCT ID: NCT01545063 Completed - Crohn's Disease Clinical Trials

CAre of Patients With PArenteral Nutrition At Home

CAPANAH
Start date: May 2012
Phase: N/A
Study type: Observational

This research aims to give an overview of a number of aspects related to the quality of care for adult patients on home parenteral nutrition. Concretely this study follows up different aspects on different moments in the care of the patient pathways: - process indicators concerning indication, parenteral nutrition, training, team access roads and the succession of complications - Outcome indicators - the health-related quality of life - discrepancies in medication use - the role of the different health care providers

NCT ID: NCT01543451 Completed - Diarrhea Clinical Trials

Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea

Start date: February 2012
Phase: Phase 2
Study type: Interventional

The main objective of this study will be to obtain data on the efficacy of elsiglutide in preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving 5-FU based chemotherapy (FOLFOX4 or FOLFIRI regimen) in comparison to placebo.

NCT ID: NCT01543178 Completed - Clinical trials for Irritable Bowel Syndrome With Diarrhea

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

TARGET3
Start date: February 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.